adult polycystic kidney disease; autosomal dominant polycystic kidney disease

From Aaushi
Jump to navigation Jump to search

Epidemiology

* thus lack of family history does not exclude diagnosis[3]

Pathology

Genetics

* mutational analysis reserved for equivocal cases following imaging[3]

Clinical manifestations

Laboratory

Radiology

Complications

Management

More general terms

More specific terms

References

  1. Harrison's Principles of Internal Medicine, 13th ed. Isselbacher et al (eds), McGraw-Hill Inc. NY, 1994, pg 1323-35
  2. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 613-14
  3. 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 Medical Knowledge Self Assessment Program (MKSAP) 11, 15, 16, 17, 18. American College of Physicians, Philadelphia 1998, 2009, 2012, 2015, 2018.
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  4. 4.0 4.1 Sallee M, Rafat C, Zahar JR, Paulmier B et al Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2009 Jul;4(7):1183-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19470662
  5. Pei Y, Obaji J, Dupuis A, Paterson AD Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009 Jan;20(1):205-12 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18945943
  6. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009 Jul;76(2):149-68 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19455193
  7. 7.0 7.1 Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C et al Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010 Aug 26;363(9):830-40. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20581392
  8. Schrier RW. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2009 Sep;20(9):1888-93. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19696226 Free Article
  9. Torres VE, Chapman AB, Devuyst O et al Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012 Dec 20;367(25):2407-18. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23121377 Free PMC Article
  10. Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008 Oct 2;359(14):1477-85. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18832246
  11. 11.0 11.1 Palmer SC Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease: A Systematic Review and Meta-analysis Ann Intern Med March 20, 2012 156:445-459 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22431677
  12. 12.0 12.1 12.2 Torres VE, Chapman AB, Devuyst O et al Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med 2017; 377:1930-1942. November 16, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29105594 Free Article <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1710030
  13. Chapman AB, Devuyst O, Eckardt KU et al Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015 Jul;88(1):17-27. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25786098 Free PMC Article
  14. Krishnappa V, Vinod P, Deverakonda D, Raina R. Autosomal dominant polycystic kidney disease and the heart and brain. Cleve Clin J Med. 2017 Jun;84(6):471-481. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28628430 Free Article
  15. 15.0 15.1 NEJM Knowledge+ Nephrology/Urology

Patient information

autosomal dominant polycystic kidney disease patient information

Database